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Background: Salivary Adenoid cystic carcinoma (SACC) patients with local invasion and lung metastasis are often
resistant to conventional therapy such as operation, chemotherapy and radiotherapy. To explore the underling
mechanisms, we studied the roles of miRNA in regulating invasiveness of SACC cells.
Methods: MicroRNA profiling was done in SACC cells with microarray. MiRNA mimics or antisense oligonucleotide
was transfected and invasiveness of SACC cells was evaluated by adhesion assay and transwell assay. The target gene of
miRNA was identified by luciferase reporter assay and “rescue” experiment. Tumor metastasis was evaluated by BALB/c-nu
mice xenografts. MiRNA and its target gene expression were identified by in-situ hybridization and immunohistochemistry
respectively, in 302 patients from affiliated hospitals of Sun Yat-sen University and in 148 patients from affiliated hospitals
of Central South University, and correlated to the clinicopathological status of the patients.
Results: MiR-320a was down-regulated in high lung metastatic ACCM and SACC-LM cells compared with the corresponding
low metastatic ACC2 and SACC-83 cells, and inhibited adhesion, invasion and migration of SACC cells by targeting integrin
beta 3 (ITGB3). In vivo, enforced miR-320a expression suppressed metastasis of SACC xenografts. In the two independent sets,
miR-320a was downregulated in primary SACCs with metastasis compared to those without metastasis, and low expression
of this miRNA predicts poor patient survival and rapid metastasis. Multivariate analysis showed that miR-320a expression was
an independent indicator of lung metastasis.
Conclusions: MiR-320a inhibits metastasis in SACCs by targeting ITGB3 and may serve as a therapeutic target and
prognostic marker in salivary cancers.
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Salivary adenoid cystic carcinoma (SACC) mainly occurs
in the salivary duct, accounting for 24% of malignant
salivary gland tumors. SACC exhibits certain unique
characteristics, such as neurotropic, infiltrative growth
and distant metastasis [1-3]. For SACC patients, distant
metastasis is a crucial prognostic factor [4,5]. Therefore,
determining the mechanisms that govern the perineural* Correspondence: songerwei02@aliyun.com; lijinsong1967@163.com
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unless otherwise stated.invasion and metastasis of SACCs is essential for the
development of novel therapeutic strategies to improve
patient survival.
MicroRNAs (miRNAs) are a class of small non-coding
RNAs (~22 nucleotides in length) that are endogenously
expressed in mammalian cells. miRNAs regulate gene
expression by repressing mRNA translation or cleaving
target mRNAs. miRNAs may function as oncogenes or
tumor suppressors by modulating multiple cellular path-
ways, including cell proliferation [6], differentiation [7,8],
apoptosis [9,10], and invasion [11-13]. There are signifi-
cant differences in the miRNA expression profiles of a
variety of human cancers, including colon, breast,is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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leukemia, compared with the corresponding normal
tissues [6,7,14]. Recently, a study found that 19 miRNAs
were upregulated and 36 miRNAs were downregulated in
primary SACC specimens, compared with matched nor-
mal samples [15]. However, the mechanisms by which
miRNAs regulate the biological characteristics of SACC
remains unclear.
Integrins are a family of transmembrane receptors that
mediate the attachment between a cell and its sur-
roundings, such as other cells or the extracellular matrix
(ECM), and play important roles in signal transduction
[16-19]. Integrins regulate cell proliferation, survival and
migration mainly through FAK (focal adhesion kinase)
and Src kinase family members [20,21]. Functional integrins
are heterodimers containing two distinct subunits, α and β.
There are 18 α subunits and 8 β subunits found in mam-
mals. Heterodimers formed between different subunits
have different structures and functions [17,18]. It has
been reported in breast, colorectal cancer and hepato-
cellular carcinoma that dysfunctions in microRNA-
regulated integrin signaling were involved in tumor
metastasis and apoptosis [10,22,23].
In the present study, we screened for differentially
expressed miRNAs in high lung metastatic SACC cells
compared with their corresponding low metastatic cells
and identified miR-320a as a metastatic repressor. We
then explored the mechanism by which miR-320a regu-
lates the invasiveness of SACC cells and the metastasis
of SACC xenografts and identified its functional target
as integrin beta 3 (ITGB3). Finally, we found significant
correlations between miR-320a expression and the clini-
copathological status and prognosis of SACC patients in
two independent sets. These findings have advanced
our knowledge of the molecular mechanisms of SACC
metastasis and provided potential markers and thera-
peutic targets for the diagnosis and treatment of SACC.
Results
Reduction of miR-320a promotes invasiveness of salivary
adenoid cystic carcinoma cells
To identify miRNAs involved in SACC metastasis, we
screened for miRNAs that are differentially expressed in
high lung metastatic ACCM cells and the parental low
metastatic ACC2 cells via microarray analysis (Additional
file 1). qRT-PCR further validated miR-320a as the most
significantly downregulated miRNA in ACCM cells
(Additional file 2). Transfection of the high lung meta-
static cells with miR-320a mimics but not the non-relevant
lin4 mimics specifically increased miR-320a levels in
ACCM and SACC-LM cell (P < 0.01, Figure 1A).
We next investigated whether ectopic expression of
miR-320a inhibited the invasiveness in SACC cells.
Transfection of miR-320a mimics remarkably inhibitedthe adhesion of ACCM cells (Figure 1B and E, P < 0.05).
Transwell assays also demonstrated that miR-320a inhib-
ited ACCM cell invasion and migration by 72% (Figure 1C
and E, P < 0.05) and 60% (Figure 1D and E, P < 0.05),
respectively. Transfection with miR-320a also inhibited
SACC-LM cell adhesion, invasion and migration by 75%
(Figure 1B and E, P = 0.001), 80% (Figure 1C and E, P =
0.008) and 82% (Figure 1D and E, P = 0.007), respectively.
In contrast, silencing miR-320a expression in the par-
ental ACC2 and SACC-83 cells using antisense oligonu-
cleotides (ASO) enhanced the invasiveness of these cells
(Additional file 3). The adhesion, invasion and migration
of ACC2 cells increased by 2-, 3-, and 2.9-fold, re-
spectively, and that of SACC-83 cells increased by 2.2-,
4.7- and 7.2-fold, respectively. Therefore, reduced miR-320a
levels contribute to enhanced invasiveness in SACC cells.
miR-320a inhibits the invasiveness of SACC cells by
targeting ITGB3
miRNAs act by binding to the 3′-untranslated region
(3′-UTR) of target genes through partial sequence hom-
ology. We predicted the target genes of miR-320a using
TargetScan and found an miR-320a recognition site in
the 3′-UTR of ITGB3 (Figure 2A). To confirm whether
ITGB3 is a target of miR-320a, we performed luciferase
reporter assays and evaluated the relative luciferase ac-
tivities in SACC cells transfected with a reporter plasmid
carrying an miR-320a target sequence (ITGB3 3′-UTR)
versus those transfected with a control plasmid. It was
shown that co-transfection with miR-320a mimics sig-
nificantly reduced the luciferase activity in ACCM and
SACC-LM cells (Figure 2B). However, when the miRNA
target sequence was mutated in the reporter plasmids
(ITGB3 3′-UTR mut), transfection with miR-320a mimics
failed to influence the relative luciferase activity, sug-
gesting that miR-320a suppresses ITGB3 expression in
SACC cells.
To study whether ITGB3 serves as a functional target
of miR-320a, we examined integrin β3 expression in these
cells. Western blot analysis showed that integrin β3 ex-
pression in ACCM and SACC-LM cells was much higher
than in the parental ACC2 and SACC-83 cells (Figure 2C).
Transfection with miR-320a mimics reduced integrin
β3 expression in ACCM and SACC-LM cells, while
transfection with the miR-320a ASO enhanced integrin
β3 expression in the parental ACC2 and SACC-83 cells.
Furthermore, FAK and Src phosphorylation was sup-
pressed by the miR-320a mimics, and enhanced by the
miR-320a ASO, suggesting that miR-320a regulates
the activity of the integrin signaling pathway. Further-
more, immunofluorescence staining demonstrated that
the cytoskeletal protein actin accumulated in clusters
and co-localized with clustered integrin β3 on the ACCM
cell surface (Figure 2D). These phenotypes were regulated
Figure 1 Ectopic expression of miR-320a inhibits the invasiveness of salivary adenoid cystic carcinoma cells. (A) miR-320a expression in SACC cells
was determined by qRT-PCR analysis. **P < 0.01 vs. parental SACC cells. ##P < 0.01 vs. mock transfection. U6 was used as an internal control.
Adhesion assays (B) and transwell assays (C, D) showed that adhesion, invasion and migration of ACCM and SACC-LM cells were inhibited by
miR-320a mimics (100×). (E) Quantification of adhesive, invasive and migratory cells assessed by adhesion assays and transwell assays. *P< 0.05; **P< 0.01
vs. mock.
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320a mimics resulted in the downregulation of integrin β3
and a ring-like distribution of actin. In contrast, in ACC2
cells, miR-320a ASO promoted the aggregation of actin
and its co-localization with clustered integrin β3 on the
cell surface.To identify whether miR-320a inhibits the invasiveness
of SACC cells by targeting ITGB3, we performed a
“rescue” experiment by co-transfecting ACCM cells
with miR-320a mimics and a pcDNA3.1 vector that ex-
presses ITGB3 with mutated miR-320a seed sequence
(ITGB3 mut) in the 3′-UTR. Western blot analysis
Figure 2 ITGB3 is an miR-320a target gene. (A) Target sequence of miR-320a in ITGB3 3′-UTR predicted by TargetScan, as well as the mutated sequence.
(B) Luciferase reporter assays were performed in ACCM and SACC-LM cells co-transfected with miR-320a-mimics and reporter vectors carrying a ITGB3
3′-UTR with a wild-type (ITGB3 3′-UTR) or mutated miR-320a (ITGB3 3′-UTR mut) response element. *P < 0.05 vs. mock transfection. (C) Integrin
β3 expression, as well as FAK and Src phosphorylation, was assessed using western blot analysis. β-actin was used as an internal control. (D)
Colocalization of integrin β3 and the cytoskeletal protein actin was illustrated by immunofluorescence staining. Nuclei: blue, scale bar: 10 μm.
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miR-320a mimics and ITGB3 mut restored integrin β3
expression, as well as FAK and Src phosphorylation, whereas
co-transfecting wild-type pcDNA3.1-ITGB3 could not
restore integrin β3 expression after silencing by miR-320a
mimics (Figure 3A). Moreover, “rescuing” integrin β3 ex-
pression in the presence of miRNA mimics restored adhe-
sion, invasion and migration of ACCM cells (Figure 3, B-E).Collectively, these data suggest that miR-320a regulates the
invasiveness of SACC cells by targeting ITGB3.
Enforced miR-320a expression inhibits ACCM xenograft
metastasis
Given that miR-320a expression inhibits the invasiveness
of SACC cells in vitro, we further assessed its effect on me-
tastasis in vivo. miR-320a was stably expressed in ACCM
Figure 3 miR-320a inhibits the invasiveness of SACC cells by targeting ITGB3. (A) Integrin β3 expression and FAK and Src phosphorylation were
determined by western blot analysis in ACCM cells transfected with miR-320a mimics alone or in combination with either pcDNA 3.1+ (Vector) or
pcDNA 3.1+ containing a wild-type (ITGB3) or mutant ITGB3 expression cassette of the miR-320a (ITGB3 mut) response element. β-actin was used
as an internal control. Adhesion, invasion and migration of ACCM cells were assessed using adhesion assays (B) and transwell assays (C, D) (100x).
(E) Quantification of adhesive, invasive and migratory ACCM cells. *P < 0.05; **P < 0.01; ***P < 0.001 vs. vector.
Sun et al. Molecular Cancer  (2015) 14:96 Page 5 of 13cells by transduction with an miRNA-expressing vector
(EmGFP-320a, Additional file 4A). As shown in Additional
file 4B, enforced miR-320a expression did not alter tumor
growth in BALB/c-nu mice inoculated with ACCM cells.However, luminescence imaging of the whole body
(Figure 4A) and harvested lungs and livers (Figure 4B)
demonstrated that ACCM cells metastasized to the lungs
and livers of tumor-bearing mice, and miR-320a expression
Figure 4 Ectopic expression of miR-320a inhibits ACCM xenograft metastasis in BALB/c-nu mice. (A) Whole-body luminal imaging was performed
in mice inoculated with ACCM stably expressing the luciferase gene. Luminal images (B) and HE staining (C) of paraffin sections (200×) of the
lungs (upper) and livers (lower) of the tumor-bearing mice. (D) Mean ± SD wet lung weight of tumor-bearing mice (n = 8/group). (E) Expression
of human HPRT mRNA relative to mouse 18S rRNA in the lungs and livers of the tumor-bearing mice was determined by qRT-PCR analysis. **P < 0.01
vs. ACC2 cells. ##P < 0.01 vs. EmGFP transfection.
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miR-320a expression inhibited metastasis in the lungs and
livers of mice bearing ACCM xenografts compared with
non-relevant miRNA (Figure 4C). Furthermore, the
average lung weight of ACCM tumor-bearing mice wasreduced by miR-320a expression (Figure 4D, n = 8,
P < 0.01). The number of metastasized tumor cells,
as quantified by qRT-PCR for human HPRT in tumor-
bearing mice, was reduced by 80% and 70% in the lungs and
livers, respectively, of animals inoculated with miR-320a-
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of the xenografts also indicated that the focal metasta-
sis of ACCM tumors was markedly reduced by miR-320a
(Additional file 4C). Therefore, miR-320a overexpression
significantly suppressed the metastasis of ACCM xenografts.
Moreover, immunohistochemical staining revealed
that miR-320a overexpression reduced integrin β3 ex-
pression by more than 60% (Additional file 4C and D)
but did not influence the percentage of proliferative
PCNA+ tumor cells (Additional file 4C and E). These
findings indicate that miR-320a inhibits SACC metastasis
in vivo, most likely by silencing ITGB3.
Low miR-320a expression indicates poor patient survival
and high SACC metastasis
We further evaluated the clinical significance of miR-320a
expression in patient prognosis and SACC metastasis.
In situ hybridization and immunohistochemical staining
(Figure 5A) demonstrated that miR-320a expression was
lower and integrin β3 expression was higher in primary
SACCs with metastasis compared with those without me-
tastasis. The difference in expression between SACCs with
metastasis and SACCs without metastasis from the af-
filiated hospitals of Sun Yat-sen University was statistically
significant (Figure 5B, P < 0.001). Spearman order cor-
relation analysis showed that integrin β3 expression in
SACCs was inversely correlated with the miR-320a level
(Additional file 5A, rs = −0.839, P < 0.001). Furthermore,
SACCs with metastasis collected at affiliated hospitals of
Central South University had remarkably low miR-320a ex-
pression and high integrin β3 expression (Figure 5C, P <
0.001), and the integrin β3 expression in the SACC paitents
was negatively correlated with miR-320a levels (Additional
file 5B, rs = −0.857, P < 0.001).
Next, we analyzed the association between miR-320a
expression and the clinicopathologic status of SACC pa-
tients (Table 1). No significant correlation was observed
between miR-320a expression and age, sex, tumor size or
TNM stage. However, the miR-320a levels were closely as-
sociated with distant metastasis in patients from the two
independent sets (P < 0.001, or P = 0.001, respectively).
Tumors with distant metastasis expressed low levels of
miR-320a. Conversely, integrin β3 expression was posi-
tively correlated with distant metastasis in SACC patients.
Furthermore, we generated Kaplan-Meier curves to
evaluate the correlation between miR-320a expression
and metastasis and the survival of the patients. The cu-
mulative metastasis rate up to 10 years was significantly
lower for patients with high miR-320a expression from
the affiliated hospitals of Sun Yat-sen University than
for those with low miR-320a expression (Figure 5D, 27.4%
vs. 52.4%, P < 0.001). The cumulative survival rate was
62.8% for patients with high miR-320a expression, whereas
it was only 44.4% for those with low miR-320a expression(Figure 5E, P = 0.001). Similar results were obtained for pa-
tients from the affiliated hospitals of Central South Univer-
sity. The cumulative metastasis rate up to 10 years was
25.9% for patients with high miR-320a expression, as
opposed to 55.9% for those with low miR-320a expres-
sion (Figure 5F, P = 0.001), and the cumulative survival
rate was 64.8% for patients with high miR-320a expres-
sion versus only 39.4% for those with low miR-320a ex-
pression (Figure 5G, P = 0.003). In contrast, high integrin
β3 expression was associated with a high metastasis rate
(Additional file 6A and C) and poor survival in the pa-
tients (Additional file 6B and D).
To determine whether miR-320a is an independent
prognostic covariate for SACCs, we carried out a multi-
variate Cox proportional hazards analysis (Additional
file 7). In the final multivariate Cox regression model,
miR-320a expression in SACCs is associated with low
lung metastasis (hazard ratio [HR] = 0.45, P < 0.001 for
patients from the affiliated hospitals of Sun Yat-sen
University; HR = 0.363, P = 0.001 for patients from the
affiliated hospitals of Central South University), inde-
pendent of other clinical covariates, suggesting that
miR-320a can be used as an independent indicator for
lung metastasis in SACC patients.
Discussion
Dysregulation of miRNAs has been well documented in
nearly all types of human malignancies, and numerous
miRNAs are involved in tumor formation and progres-
sion by regulating the expression and action of many onco-
genes and tumor suppressor genes. Previously, miR-320a
was shown to be downregulated in colon cancer tissues
and cancer cell lines, and ectopic expression of miR-320a
suppressed the growth of colon cancer cells by directly
targeting β-catenin [24]. In leukemia cells, enforced miR-
320a expression suppresses transferrin receptor 1 expression
and cell proliferation [25]. Furthermore, the miR-320a ex-
pression levels were significantly decreased in liver me-
tastasis tissues compared with matched primary colorectal
cancer tissues [26]. In our study, CCK8 assays and
Annexin V/PI assays demonstrated that miR-320a ex-
pression did not influence the proliferation and apop-
tosis of SACC cells (data not shown). In vivo experiments
also illustrated that miR-320a did not regulate tumor
growth in ACC xenografts. However, reduced miR-320a
expression is critical for the invasiveness of SACC cells,
and ectopic miR-320a expression represses SACC tumor
metastasis by silencing ITGB3. These results indicate that
miR-320a primarily regulates the metastasis of SACCs. In
addition, our study suggested that miR-320a exerts its
anti-metastatic function by targeting ITGB3, a previously
unidentified miR-320a target. This might explain the vari-
ous functions of miR-320a among different cancer types
while also suggesting that distinct features of SACC cells
Figure 5 miR-320a downregulation correlates with metastasis and poor patient survival in SACCs. (A) In situ hybridization for miR-320a and
immunohistochemical staining for integrin β3 in primary SACCs with metastasis vs. those without metastasis (200×). Quantification of miR-320a and
integrin β3 expression in primary SACC samples from the affiliated hospitals of Sun Yat-sen University (B) or from the affiliated hospitals of Central
South University (C). ***P < 0.001. Kaplan-Meier curves for SACC patients from the affiliated hospitals of Sun Yat-sen University comparing miR-320a
expression and metastasis (D) or miR-320a expression and survival (E) was analyzed by the log rank test. Kaplan-Meier curves for SACC patients from
the affiliated hospitals of Central South University comparing miR-320a expression and metastasis (F) or miR-320a expression and survival (G).
The median value was used to distinguish high expression and low expression.
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peutic strategy.
Local invasion and distant metastasis are the main
causes of death in SACC patients. Therefore, determining
the mechanisms that govern the metastasis of SACCs is es-
sential for the development of novel therapeutic strategiesto improve patient survival. In the present study, we found
that ectopic miR-320a expression represses the invasive-
ness of SACC cells and the metastasis of SACC xenograft
tumors, suggesting that miR-320a may be an effective
therapeutic target. In contrast to artificially synthetic
siRNAs, microRNAs are endogenous molecules that exist
Table 1 Correlation among clinicopathologic status and the expression of miR-320a or integrin β3 in SACC patients
A. Correlation among clinicopathologic status and the expression of miR-320a or integrin β3 in SACC patients of Sun Yat-sen University
Characteristics miR-320a (%) Integrin β3 (%)
No. of low expression No. of high expression P No. of low expression No. of high expression P
Sex 0.905 0.097
Male 83 (61.9) 51 (38.1) 45 (33.6) 89 (66.4)
Female 106 (63.1) 62 (36.9) 73 (43.5) 95 (56.5)
Age 0.153 0.814
<50 82 (58.2) 59 (41.8) 54 (38.3) 87 (61.7)
≥50 107 (66.5) 54 (33.5) 64 (39.8) 97 (60.2)
Tumor Size 0.801 0.319
T1-2 125 (61.9) 77 (38.1) 83 (41.1) 119 (58.9)
T3-4 64 (64.0) 36 (36.0) 35 (35.0) 65 (65.0)
Node metastasis 0.029 0.032
N0 154 (59.9) 103 (40.1) 107 (41.6) 150 (58.4)
N1 35 (77.8) 10 (22.2) 11 (24.4) 34 (75.6)
TNM stage 0.074 0.044
I-II 95 (57.9) 69 (42.1) 73 (44.5) 91 (55.5)
III-IV 94 (68.1) 44 (31.9) 45 (32.6) 93 (67.4)
Distant Metastasis <0.001 0.001
No 90 (52.3) 82 (47.7) 81 (47.1) 91 (52.9)
Yes 99 (76.2) 31 (23.8) 37 (28.5) 93 (71.5)
Status 0.002 0.009
Survival 84 (54.2) 71 (45.8) 72(46.5) 83 (53.5)
Death 105 (71.4) 42 (28.6) 46(31.3) 101 (68.7)
B. Correlation among clinicopathologic status and the expression of miR-320a or integrin β3 in SACC patients of Central South University
Sex 0.496 0.865
Male 53 (66.2) 27 (33.8) 29 (36.2) 51 (63.8)
Female 41 (60.3) 27 (39.7) 26 (38.2) 42 (61.8)
Age 0.170 0.609
<50 47 (58.0) 34 (42.0) 32 (39.5) 49 (60.5)
≥50 47 (70.1) 20 (29.9) 23 (34.3) 44 (65.7)
Tumor Size 0.601 0.861
T1-2 60 (65.2) 32 (34.8) 35 (38.0) 57 (62.0)
T3-4 34 (60.7) 22 (39.3) 20 (35.7) 36 (64.3)
Node metastasis 0.811 0.469
N0 80 (63.0) 47 (37.0) 49 (38.6) 78 (61.4)
N1-N2 14 (66.7) 7 (33.3) 6 (28.6) 15 (71.4)
TNM stage 0.392 0.608
I-II 56 (66.7) 28 (33.3) 33 (39.3) 51 (60.7)
III-IV 38 (59.4) 26 (40.6) 22 (34.4) 42 (65.6)
Distant Metastasis 0.001 0.004
No 42 (51.2) 40 (48.8) 39 (47.6) 43 (52.4)
Yes 52 (78.8) 14 (21.2) 16 (24.2) 50 (75.8)
Status 0.004 0.017
Survival 37 (51.4) 35 (48.6) 34 (47.2) 38 (52.8)
Death 57 (75.0) 19 (25.0) 21 (27.6) 55 (72.4)
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off-target silencing effects [27,28]. In addition, because a
microRNA molecule targets a set of coding genes rather
than a single gene, therapies based on microRNA interfer-
ence could enable more potent cancer treatments by
targeting multiple molecular pathways.
In routine clinical practice, the TNM staging system is
the key prognostic determinant for patients with salivary
adenoid cystic carcinoma. However, large variations in
the clinical outcomes of patients with the same cancer
stage have been reported, suggesting that the present
staging system is not adequate for prognosis. Here, we
developed a miRNA signature that was predictive of me-
tastasis in SACC patients, independent of TNM stage.
TNM staging is performed mainly on the basis of ana-
tomical information; conversely, the miRNA signature
could show the biological characteristics of the SACCs.
Identifying miRNAs in patients using quantitative RT-
PCR might be a straightforward and clinically applicable
procedure. Furthermore, microRNAs are relatively stable
compared with other biological macromolecules. miRNAs
can be well preserved in tissue samples, even after
formalin-fixation and paraffin-embedding, and they can
be efficiently extracted and evaluated [29]. Moreover,
microRNAs released from tumor cells are protected in
membrane-derived exosomes and are thus stable in
various bodily fluids, including serum and plasma. Al-
terations to the microRNA profile in many types of
bodily fluids may reflect potential physiological and/or
pathological conditions [30,31]. All specimens in our study
were obtained from patients in China, and additional sets
of independent samples from non-Asian patients will be
needed to confirm our findings.
Conclusions
In summary, we found that miR-320a was downregulated
in metastatic SACC cells, enabling the overexpression of
its target ITGB3. Upregulated ITGB3 contributed to en-
hanced cell attachment, invasion and cancer metastasis.
These results suggest that miR-320a is an effective metas-
tasis inhibitor for SACC. We also identified a novel
miR-320a target, ITGB3, in SACC cells, which may be a
distinct feature of SACCs. Finally, miR-320a serves as a
metastasis prediction marker independent of TNM sta-
ging. These findings provide a strong rationale for the
potential use of miR-320a as a therapeutic target and
prognostic biomarker. The findings of this study were
summarized as an illustration (Additional file 8).
Methods
Cell culture
The human salivary adenoid cystic carcinoma cell lines
ACC2 and ACCM were purchased from the Type Culture
Collection of the Chinese Academy of Sciences (Shanghai,China). SACC-83 and SACC-LM were purchased from
Peking University (Beijing, China). ACCM and SACC-LM
are highly metastatic cells derived from lung metastases
of ACC2 and SACC-83 xenografts, respectively [32,33].
All cells were cultivated in RPMI-1640 medium (Gibco,
Rockville, MD) supplemented with 10% FBS (Invitrogen,
Carlsbad, CA).
MiRNA microarray analysis
Microarray analyses were performed in ACC2 and ACCM
cells as described previously [34]. A heat map demon-
strating the average levels of microRNAs, which are dif-
ferentially expressed in ACCM vs. ACC2, was created using
DMVS 2.0 software (Chipscreen Biosciences, Shenzhen,
China). The differentially expressed microRNAs are listed
in Supplementary Table 1.
Transfection
All miRNA mimics and antisense oligonucleotides (ASOs)
for miRNA were obtained from GenePharma (Shanghai,
China). Cells were transfected with 30 nM miRNA mimics
or ASOs using Lipofectamine 2000 (Invitrogen). The
EmGFP-miR-320a plasmid was also obtained from Gene-
Pharma, and blasticidin (Sigma, St Louis, MO) was used
to select transfected ACCM cells. ITGB3 cDNA carrying a
wild-type 3′-UTR or a 3′-UTR containing mutated seed
sequence for miR-320a (ITGB3 mut) were cloned into
pcDNA 3.1 for “rescue” experiments.
Quantitative RT-PCR
Real-time PCR was performed using a LightCycler 480
(Roche, Basel, Switzerland). Reactions were run in triplicate
in three independent experiments. qRT-PCR for miRNA
was performed using the Real-time PCR Universal Reagent
(GenePharma). U6 was used as an internal control.
Western blot analysis
Protein extracts were resolved via 8% SDS-PAGE, trans-
ferred onto polyvinylidene difluoride membranes (BioRad,
Berkeley, CA), probed with antibodies against human
integrin β3 (Abcam, Cambridge, UK), p-FAK (Y397),
FAK, p-Src (Y416), Src (Cell signaling, Boston, MA) or
β-actin (Proteintech, Chicago, IL) followed by a peroxidase-
conjugated secondary antibody (Proteintech), and then
visualized by chemiluminescence (ImageQuant RT ECL,
GE, Fairfield, CT).
Adhesion assay
Fibronectin-coated 24-well plates (Corning, New York,
NY) were seeded with, 1 × 104 cells/well and incubated
for 15 min, after which the non-adherent cells were washed
away and the adherent cells were fixed in 4% paraformalde-
hyde, stained with crystal violet and counted (5 random
100× fields per well). Three independent experiments
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age ± SD [35].Transwell assay
A total of 1 × 105 cells were seeded into the upper cham-
ber of a polycarbonate transwell filter chamber (Corning)
and incubated for 22 h. For the invasion assays, the upper
chamber was coated with Basement Membrane (R&D,
Minneapolis, MN). Cells on the lower membrane sur-
face were fixed in 4% paraformaldehyde, stained with
crystal violet and counted (5 random 100× fields per well).
Three independent experiments were performed and the
data are presented as the average ± SD.Luciferase reporter assay
We cloned the miR-320a response element (wild type or
mutant) of the 3′-UTR of ITGB3 into the pMIR-REPORT
plasmid downstream of the luciferase reporter gene. Lucif-
erase activity was assayed using a luciferase assay kit
(Promega, Madison, WI), and the target effect was expressed
as the relative luciferase activity of the reporter vector with
the target sequence over that of the vector without the
target sequence.Immunofluorescence staining
Cells were stained for immunofluorescence on cover-
slips. After fixation and permeabilization, the cells were
incubated with primary antibodies against integrin β3 or
FITC-phalloidin (Sigma) and then incubated with Alex
555-conjugated secondary antibodies (Invitrogen). The
coverslips were counterstained with DAPI and imaged
under a TCS SP5 confocal microscope (Leica, Solms,
Germany).Tumor xenografts
A total of 5 × 106 ACC2 or ACCM cells, either untrans-
duced or transduced with the miRNA-expressing vector
EmGFP-miR-320a, were injected into the salivary site of
5-week-old BALB/c-nu mice. After tumors were de-
tected, the tumor size was measured and calculated:
Volume (mm3) = length × width2 × 0.5. Tumor xenografts,
as well as whole lung and liver tissues, were then harvested,
weighed and snap-frozen in liquid nitrogen. To evaluate
in vivo metastasis, fluorescence images of whole mice or
their lungs and livers were acquired using an IVIS Lumina
Imaging System (Xenogen, Alameda, CA), and portions of
the lung and liver tissues were used for qRT-PCR for
hHPRT (human hypoxanthine-guanine phosphoribosyl-
transferase) expression. Cryosections (4 μm) were stained
with hematoxylin and eosin (HE) and used for immuno-
histochemistry. The procedures were approved by Sun
Yat-sen University Animal Care and Use Committee.Patients and tissue samples
Two independent retrospective SACC patient cohorts
were studied, including 302 patients from the affiliated
hospitals of Sun Yat-sen University, such as Sun Yat-sen
Memorial Hospital, the First Affiliated Hospital and the
Hospital of Stomatology (Guangzhou, China), and 148
patients from the affiliated hospitals of Central South
University, such as Xiangya Stomatological Hospital, the
Second Xiangya Hospital (Changsha, China) between Jan
1, 1999, and Dec 31, 2008. None of the patients received
any chemotherapy or radiotherapy prior to surgery. The
tumors were staged according to the TNM staging sys-
tem. The tissues were obtained from the respective
pathology departments, and histological diagnosis and
scoring of all the cases were performed by two independ-
ent pathologists (Yanyang Chen and Yang Li). Survival
time was calculated from the date of surgery to the date of
death or to the last follow-up. The date of death was ob-
tained from patient records or through follow-up tele-
phone calls. This study was approved by the institutional
ethical review boards of both hospitals, and written in-
formed consent was obtained from all patients.
In situ hybridization
This assay was performed according to the manufacturer’s
protocol (Exiqon, Vedbaek, Denmark). Briefly, after
demasking, microRNA was hybridized to 5′-DIG-labeled
LNA™ probes. Then, the digoxigenin was recognized by a
specific anti-DIG antibody that is directly conjugated to
alkaline phosphatase. The nuclei were counterstained with
hematoxylin.
Immunohistochemistry
For immunohistochemistry [36], the samples were incu-
bated with an integrin β3 antibody at 4°C overnight.
The sections were then treated with a secondary anti-
body, followed by further incubation with a streptavidin-
horseradish peroxidase complex. Diaminobenzidine (Dako,
Carpinteria, CA) was used as a chromogen, and the nuclei
were counterstained with hematoxylin.
Scoring of ISH and IHC
In each section, 5 fields of 200 tumor cells were counted
randomly, and the scores for miR-320a and integrin β3
were determined by combining the proportion of posi-
tively stained tumor cells and the intensity of staining.
The proportion of positively stained tumor cells was
graded from 0 to 3 (0, <5% positive cells; 1, 5-25%; 2,
26-50%; 3, >50%). The intensity of staining was recorded
on a scale of 0 (no staining), 1 (weak staining, light blue
or yellow), 2 (moderate staining, blue or yellow), and 3
(strong staining, dark blue or yellow). For tumors that
showed heterogeneous staining, the predominant pattern
was taken into account for scoring. The staining index
Sun et al. Molecular Cancer  (2015) 14:96 Page 12 of 13(SI) was calculated as follows: staining index = proportion
of positively stained tumor cells × staining intensity. Using
this method, the expression of miR-320a and integrin β3
was evaluated by the SI and scored as 0, 1, 2, 3, 4, 6, or 9.
A composite score greater than the median value was con-
sidered to be high expression, and composite scores less
than or equal to the median value were considered to be
low expression.
Statistical analysis
All statistical analyses were performed using SPSS 17.0
software for Windows (SPSS Inc., Chicago, IL). The Chi-
squared test was used to analyze the relationship between
miR-320a or integrin β3 expression and clinicopathologic
characteristics. To measure the association between
pairs of variables, Spearman order correlations were run.
Kaplan-Meier survival curves were plotted, and the log-
rank test was performed. The significance of various
variables for lung metastasis was analyzed by the Cox
proportional hazards model in a multivariate analysis. All
experiments with cell cultures were performed at least
in triplicate. The results are expressed as the mean ± SD.
P < 0.05 was considered statistically significant.
Additional files
Additional file 1: MicroRNA microarray analysis comparing ACC2
and ACCM cells.
Additional file 2: The differential expression of miRNAs in the ACCM
and ACC2 cells was validated using qRT-PCR analysis. U6 was used as
an internal control.
Additional file 3: Reduction of miR-320a promotes the invasiveness
of SACC cells. (A) miR-320a expression in SACC cells was determined
using qRT-PCR analysis. *P < 0.05; **P < 0.01 vs. mock transfection. U6 was
used as an internal control. An adhesion assay (B) and transwell assay (C, D)
showed that the adhesion, invasion and migration of ACC2 and SACC-83
cells were enhanced by miR-320a ASO (100x). (E) Quantification of the
adhesive, invasive and migratory cells assessed using the adhesion and
transwell assays. *P < 0.05; **P < 0.01 vs. mock.
Additional file 4: MiR-320a suppresses integrin β3 expression in
ACCM cells implanted in BALB/c-nu mice. (A) Transfection with the
EmGFP-320a vector specifically enhances miR-320a expression in ACCM
cells as determined by qRT-PCR. (B) Tumor volumes of mice inoculated
with ACC2 cells or ACCM cells stably expressing miR-320a. (C) HE staining
(200x) of the tumor and immunohistochemical staining (400x) for integrin
β3 and PCNA. The white arrows indicate focal metastases. The percentages
of integrin β3 (D) and PCNA (E) positive cells in the tumor section are
analyzed. **P < 0.01 vs. ACC2 cells. ##P < 0.01 vs. EmGFP transfection.
Additional file 5: MiR-320a expression was negatively correlated
with integrin β3 expression in SACCs. Associations between miR-320a
expression and integrin β3 expression in SACC samples from affiliated
hospitals of Sun Yat-sen University (A) or from affiliated hospitals of
Central South University (B) were analyzed using Spearman’s rank order
correlation coefficient.
Additional file 6: High expression of integrin β3 indicates poor
patient survival and high risk of SACC metastasis. Kaplan-Meier curves
for SACC patients from affiliated hospitals of Sun Yat-sen University plotted
according to integrin β3 expression and metastasis difference (A) or plotted
according to integrin β3 expression and survival difference (B) were
analyzed using the log rank test. Kaplan-Meier curves for SACC patients fromaffiliated hospitals of Central South University plotted according to integrin
β3 expression and metastasis difference (C) or plotted according to integrin
β3 expression and survival difference (D). The median level was used to
distinguish high expression and low expression.
Additional file 7: Multivariate analysis of various variables for lung
metastasis in SACC patients using Cox regression analysis.
Additional file 8: Schematic summary of the findings of this study.
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